Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 1 5 versus M PREDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 1 5 versus M PREDROL.
DEXONE 1.5 vs M-PREDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a long-acting glucocorticoid receptor agonist that suppresses inflammation and immune responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
Methylprednisolone is a glucocorticoid receptor agonist. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of pro-inflammatory cytokines, chemokines, and adhesion molecules. It also inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
1.5 mg orally once daily
4 to 48 mg/day orally or intramuscularly in divided doses every 12 hours; for acute conditions, up to 120 mg/day intravenously in divided doses every 4-6 hours.
None Documented
None Documented
Terminal half-life approximately 3-4 hours (dexamethasone), with clinical effects persisting 36-54 hours due to glucocorticoid receptor-mediated actions.
Terminal elimination half-life: 2–4 hours. Clinical context: shorter than other corticosteroids; requires multiple daily doses for sustained anti-inflammatory effect.
Renal (primarily as metabolites, ~60%), biliary/fecal (~30%), with <5% excreted unchanged.
Primarily hepatic metabolism; <20% excreted unchanged in urine. Negligible biliary/fecal elimination.
Category C
Category C
Corticosteroid
Corticosteroid